myelodysplastic syndrome
Conditions
Interventions
control group:the primary drug treatment
arsenic-containing traditional Chinese medicine compound treated group:Qinghuang Powder (Realgar 0.1g Indigo Naturalis 0.2g Capsule) and the primary drug treatment
Sponsors
Medical Ethics Committee Xiyuan Hospital China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1)The first diagnosis of MDS at the time of discharge: meeting the "Chinese Diagnosis and Treatment Guidelines for Myelodysplastic Syndromes". The signed informed consent form will pose an improper threat to the privacy of the subjectSouth (2019) minimum definitive diagnostic criteria and World Health Organization (WHO) Classification of Blood Myeloid Tumors(2016) diagnostic criteria; (2) Received 2 courses of treatment (each course of treatment is 3 months) during the study time.Arsenic-containing traditional Chinese medicine compound treatment; (3) Age: 18 years old= age = 90 years old gender is not limited.
Exclusion criteria
Exclusion criteria: (1) Patients with severe organ dysfunction or other malignant tumors; (2) Have undergone allo-HSCT; (3) Patients with incomplete case data (flow cytometry antibody immunological indicators genetic test results); (4)The patient has explicitly refused to use medical records.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Blood Count;Bone Marrow Biopsy Results;Flow Cytometry Antibody Markers;Status of Gene Mutations; | — |
Secondary
| Measure | Time frame |
|---|---|
| survival conditon; | — |
Countries
China
Contacts
Public ContactTang Xudong
Xiyuan Hospital affiliated to China Academy of Chinese Medical Sciences
Outcome results
None listed